Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with isoxicam and catabolin.

H Sheppeard, K G Couchman

    British Journal of Clinical Pharmacology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    This study investigated the impact of isoxicam on glycosaminoglycan (GAG) release in a cartilage model. Isoxicam demonstrated a potential to reduce cartilage resorption, suggesting it may not harm cartilage metabolism.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.

    Human molecular genetics·2000
    Same author

    Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients.

    Anaesthesia and intensive care·1992
    Same author

    Rheumatic disease in a Philippine village. II: a WHO-ILAR-APLAR COPCORD study, phases II and III.

    Rheumatology international·1991
    Same author

    Rehabilitation in chronic back pain: employment status after four years.

    The New Zealand medical journal·1990
    Same author

    Cauda equina syndrome in ankylosing spondylitis diagnosed by computed tomography.

    The New Zealand medical journal·1987
    Same author

    Transcutaneous electrical nerve stimulation (TNS) and its relationship to placebo therapy: a review.

    The New Zealand medical journal·1987
    Same journal

    N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

    British journal of clinical pharmacology·2026
    Same journal

    Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

    British journal of clinical pharmacology·2026
    Same journal

    The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

    British journal of clinical pharmacology·2026
    Same journal

    Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

    British journal of clinical pharmacology·2026
    Same journal

    UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

    British journal of clinical pharmacology·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Cell Biology

    Background:

    • Synovial cells secrete catabolin, a protein factor that stimulates chondrocytes to resorb matrix and release glycosaminoglycan (GAG).
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used, but their effects on cartilage metabolism require thorough investigation.

    Purpose of the Study:

    • To evaluate the effect of isoxicam on GAG production in a catabolin-induced cartilage resorption system.
    • To determine if isoxicam impacts inherent cartilage breakdown or catabolin-mediated GAG release.

    Main Methods:

    • A tissue culture system using bovine nasal septum was established.
    • The system incorporated pooled porcine synovial tissue to generate catabolin.
    • Isoxicam was added to the culture medium at varying concentrations (5-50 µg/mL) to assess its impact on GAG release.

    Related Experiment Videos

    Main Results:

    • Inherent GAG release from cartilage breakdown was 49.7% after 8 days.
    • Addition of synovial cells (catabolin) increased GAG release to 83.6%.
    • Isoxicam (5-30 µg/mL) significantly reduced catabolin-induced GAG release to 70.9%; higher concentrations had no effect on inherent breakdown.

    Conclusions:

    • Isoxicam appears unlikely to impair cartilage metabolism.
    • The NSAID may potentially decrease cartilage resorption mediated by catabolin.